Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 203

1.

Triplet chemotherapy vs doublet chemotherapy plus bevacizumab in metastatic, recurrent, and persistent cervical cancer.

Choi HJ, Lee YY, Choi CH, Kim TJ, Lee JW, Bae JH, Bae DS, Kim BG.

Curr Probl Cancer. 2020 Feb 12:100557. doi: 10.1016/j.currproblcancer.2020.100557. [Epub ahead of print]

PMID:
32067746
2.

Impact of Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers and Thiazide Diuretics on Survival of Ovarian Cancer Patients.

Cho MA, Jeong SY, Sohn I, Kim MS, Kang JH, Paik ES, Lee YY, Choi CH.

Cancer Res Treat. 2020 Jan 16. doi: 10.4143/crt.2019.509. [Epub ahead of print]

3.

Phase I Study of a B Cell-Based and Monocyte-Based Immunotherapeutic Vaccine, BVAC-C in Human Papillomavirus Type 16- or 18-Positive Recurrent Cervical Cancer.

Choi CH, Choi HJ, Lee JW, Kang ES, Cho D, Park BK, Kim YM, Kim DY, Seo H, Park M, Kim W, Choi KY, Oh T, Kang CY, Kim BG.

J Clin Med. 2020 Jan 5;9(1). pii: E147. doi: 10.3390/jcm9010147.

4.

Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer.

Jeong SY, Choi CH, Kim TJ, Lee JW, Kim BG, Bae DS, Lee YY.

J Ovarian Res. 2019 Dec 31;13(1):1. doi: 10.1186/s13048-019-0602-5.

5.

Effectiveness of adjuvant treatment for morcellated, International Federation of Gynecology and Obstetrics stage I uterine leiomyosarcoma: A Korean multicenter study.

Kim SI, Choi CH, Kim K, Hong DH, Park JY, Kwon BS, Lee KH, Hong DG, Shin SJ, Park SI, Kim YH, Lee SH, Lee S, Hong JH, Lee JY, Kim YB, No JH, Suh DH.

J Obstet Gynaecol Res. 2020 Feb;46(2):337-346. doi: 10.1111/jog.14171. Epub 2019 Dec 9.

PMID:
31814199
6.

Prevalence and oncologic outcomes of BRCA1/2 mutation and variant of unknown significance in epithelial ovarian carcinoma patients in Korea.

Seo JH, Jeong SY, Kim MS, Kang JH, Paik ES, Lee YY, Kim TJ, Lee JW, Kim BG, Bae DS, Choi CH.

Obstet Gynecol Sci. 2019 Nov;62(6):411-419. doi: 10.5468/ogs.2019.62.6.411. Epub 2019 Oct 11.

7.

CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer.

Kim J, Cho YJ, Ryu JY, Hwang I, Han HD, Ahn HJ, Kim WY, Cho H, Chung JY, Hewitt SM, Kim JH, Kim BG, Bae DS, Choi CH, Lee JW.

Gynecol Oncol. 2020 Jan;156(1):211-221. doi: 10.1016/j.ygyno.2019.11.004. Epub 2019 Nov 24.

PMID:
31776040
8.

Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers.

Sa JK, Hwang JR, Cho YJ, Ryu JY, Choi JJ, Jeong SY, Kim J, Kim MS, Paik ES, Lee YY, Choi CH, Kim TJ, Kim BG, Bae DS, Lee Y, Her NG, Shin YJ, Cho HJ, Kim JY, Seo YJ, Koo H, Oh JW, Lee T, Kim HS, Song SY, Bae JS, Park WY, Han HD, Ahn HJ, Sood AK, Rabadan R, Lee JK, Nam DH, Lee JW.

Genome Biol. 2019 Nov 26;20(1):253. doi: 10.1186/s13059-019-1848-3.

9.

Comparison between Laparoendoscopic Single-Site and Conventional Laparoscopic Surgery in Mature Cystic Teratoma of the Ovary.

Kim MS, Choi CH, Lee JW, Kim BG, Bae DS, Kim TJ.

Gynecol Minim Invasive Ther. 2019 Oct 24;8(4):155-159. doi: 10.4103/GMIT.GMIT_3_19. eCollection 2019 Oct-Dec.

10.

Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study.

Paik ES, Lee YJ, Lee JY, Shin W, Park SY, Kim SI, Kim JW, Choi CH, Kim BG.

J Clin Med. 2019 Nov 8;8(11). pii: E1920. doi: 10.3390/jcm8111920.

11.

Pretreatment Lymph Node Metastasis as a Prognostic Significance in Cervical Cancer: Comparison between Disease Status.

Jeong SY, Park H, Kim MS, Kang JH, Paik ES, Lee YY, Kim TJ, Lee JW, Kim BG, Bae DS, Choi CH.

Cancer Res Treat. 2019 Oct 29. doi: 10.4143/crt.2019.328. [Epub ahead of print]

12.

An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION.

Lee JY, Yi JY, Kim HS, Lim J, Kim S, Nam BH, Kim HS, Kim JW, Choi CH, Kim BG; KGOG investigators.

Jpn J Clin Oncol. 2019 Aug 1;49(8):789-792. doi: 10.1093/jjco/hyz085.

PMID:
31671191
13.

Anti-Tumor Effects of Wee1 Kinase Inhibitor with Radiotherapy in Human Cervical Cancer.

Lee YY, Cho YJ, Shin SW, Choi C, Ryu JY, Jeon HK, Choi JJ, Hwang JR, Choi CH, Kim TJ, Kim BG, Bae DS, Park W, Lee JW.

Sci Rep. 2019 Oct 28;9(1):15394. doi: 10.1038/s41598-019-51959-3.

14.

A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D.

Lee JY, Kim JW, Lim MC, Kim S, Kim HS, Choi CH, Yi JY, Park SY, Kim BG; KGOG investigators.

J Gynecol Oncol. 2019 Nov;30(6):e112. doi: 10.3802/jgo.2019.30.e112.

15.

Prognostic Model for Survival and Recurrence in Patients with Early-Stage Cervical Cancer: A Korean Gynecologic Oncology Group Study (KGOG 1028).

Paik ES, Lim MC, Kim MH, Kim YH, Song ES, Seong SJ, Suh DH, Lee JM, Lee C, Choi CH.

Cancer Res Treat. 2020 Jan;52(1):320-333. doi: 10.4143/crt.2019.124. Epub 2019 Aug 5.

16.

Comparison of laparoscopic and abdominal radical hysterectomy in early stage cervical cancer patients without adjuvant treatment: Ancillary analysis of a Korean Gynecologic Oncology Group Study (KGOG 1028).

Paik ES, Lim MC, Kim MH, Kim YH, Song ES, Seong SJ, Suh DH, Lee JM, Lee C, Choi CH.

Gynecol Oncol. 2019 Sep;154(3):547-553. doi: 10.1016/j.ygyno.2019.06.023. Epub 2019 Jul 1.

PMID:
31272738
17.

Prediction of survival outcomes in patients with epithelial ovarian cancer using machine learning methods.

Paik ES, Lee JW, Park JY, Kim JH, Kim M, Kim TJ, Choi CH, Kim BG, Bae DS, Seo SW.

J Gynecol Oncol. 2019 Jul;30(4):e65. doi: 10.3802/jgo.2019.30.e65. Epub 2019 Mar 11.

18.

Prognostic value of ADC quantification for clinical outcome in uterine cervical cancer treated with concurrent chemoradiotherapy.

Gu KW, Kim CK, Choi CH, Yoon YC, Park W.

Eur Radiol. 2019 Nov;29(11):6236-6244. doi: 10.1007/s00330-019-06204-w. Epub 2019 Apr 12.

PMID:
30980126
19.

Prognostic factors for recurrence and survival in uterine leiomyosarcoma: Korean single center experience with 50 cases.

Paik ES, Kang JH, Kim J, Lee YJ, Choi CH, Kim TJ, Kim BG, Bae DS, Lee JW.

Obstet Gynecol Sci. 2019 Mar;62(2):103-111. doi: 10.5468/ogs.2019.62.2.103. Epub 2019 Feb 12.

20.

Correction: Molecular Chaperone HSP90 Is Necessary to Prevent Cellular Senescence via Lysosomal Degradation of p14ARF.

Han SY, Ko A, Kitano H, Choi CH, Lee MS, Seo J, Fukuoka J, Kim SY, Hewitt SM, Chung JY, Song J.

Cancer Res. 2018 Dec 15;78(24):6903. doi: 10.1158/0008-5472.CAN-18-3311. No abstract available.

Supplemental Content

Loading ...
Support Center